WINT Share Price | Windtree Therapeutics, Inc. Stock Analysis & Recommendation

Q: How big is Windtree Therapeutics, Inc.?

Market Cap: As of Jun 18, Windtree Therapeutics, Inc. has a market capitalization of 2.19 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Windtree Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -16.04 million.Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 13.18 million, while total assets were reported at 27.88 million.

Q: What does Windtree Therapeutics, Inc. do?

Overview: Windtree Therapeutics, Inc. is a biotechnology company focused on developing KL4 surfactant therapies for respiratory diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot: Most recent Net Profit: -4 Million (Quarterly Results - Mar 2025) Market-cap: USD 2.19 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: 0.00 Return on Equity: -224.59% Price to Book: 0.19Contact Details: Address: 2600 Kelly Rd Ste 100, WARRINGTON PA: 18976-3652 Tel: 1 215 4889300 Fax: 1 215 4889301 Website: http://www.windtreetx.com/

Q: Who are in the management team of Windtree Therapeutics, Inc.?

As of March 2022, the management team of Windtree Therapeutics, Inc. includes the following individuals:- Mr. James Huang: Independent Chairman of the Board- Mr. Craig Fraser: President, Chief Executive Officer, Director- Dr. Pratap Paruchuru: Executive Director of Clinical DevelopmentAdditionally, the Board of Directors features several independent directors, including Mr. Daniel Geffken, Mr. John Leone, Mr. Joseph Mahady, Mr. Bruce Peacock, and Dr. Brian Schreiber.

Q: Is Windtree Therapeutics, Inc. overvalued or undervalued?

As of 16 August 2019, the valuation grade for Windtree Therapeutics, Inc. moved from risky to does not qualify, indicating significant concerns regarding its financial health. The company is currently considered overvalued given its financial ratios, including a Price to Book Value of 0.18 and an EV to Capital Employed of 0.19, both of which suggest poor asset utilization and financial performance. Additionally, the company has a negative ROCE of -217.14% and ROE of -224.59%, highlighting severe inefficiencies in generating returns for shareholders.In comparison to its peers, Windtree Therapeutics, Inc. has an EV to EBITDA of -0.09, which is less favorable than Aileron Therapeutics, Inc. at -1.6430 and Soligenix, Inc. at -0.5878. This further reinforces the notion that Windtree is not only struggling in its operational metrics but also underperforming relative to similar companies in the sector. Overall, the combination of poor financial ratios and a lack of positive returns suggests that Windtree Therapeutics, Inc. is overvalued in the current market context.

Q: Is Windtree Therapeutics, Inc. technically bullish or bearish?

As of 11 September 2025, the technical trend for Windtree Therapeutics, Inc. has changed from mildly bearish to bearish. The current technical stance is bearish with weak strength. Key indicators include a bearish signal from the daily moving averages, while the weekly and monthly MACD are mildly bullish, indicating some divergence. The weekly RSI is bearish, and both the KST and Dow Theory are bearish across the weekly and monthly time frames. In terms of performance, the stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -99.56% versus the S&P 500's 12.22%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

71.84 k

Shareholding (Sep 2025)

FII

0.00%

Held by 3 FIIs

DII

99.75%

Held by 0 DIIs

Promoter

0.00%

How big is Windtree Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Windtree Therapeutics, Inc. has a market capitalization of 2.19 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -16.04 million over the latest four quarters. The company's shareholder's funds are 13.18 million, and total assets are 27.88 million as of Dec 24.

View full answer

What does Windtree Therapeutics, Inc. do?

22-Jun-2025

Windtree Therapeutics, Inc. is a biotechnology company developing KL4 surfactant therapies for respiratory diseases, classified as a micro-cap with a market cap of $2.19 million and a recent net profit loss of $4 million. The company has no debt and does not pay dividends.

View full answer

Who are in the management team of Windtree Therapeutics, Inc.?

22-Jun-2025

As of March 2022, Windtree Therapeutics, Inc.'s management team includes Mr. James Huang (Independent Chairman), Mr. Craig Fraser (President and CEO), and Dr. Pratap Paruchuru (Executive Director of Clinical Development), along with several independent directors on the Board.

View full answer

Is Windtree Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of August 16, 2019, Windtree Therapeutics, Inc. is considered overvalued due to poor financial ratios, including a Price to Book Value of 0.18 and negative returns on capital and equity, indicating significant inefficiencies compared to its peers.

View full answer

Is Windtree Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 11, 2025, Windtree Therapeutics, Inc. is in a bearish trend with weak strength, indicated by bearish daily moving averages and underperformance of -99.56% year-to-date compared to the S&P 500's 12.22%.

View full answer

Compare Windtree Therapeutics, Inc. with Similar Stocks

Silo Pharma, Inc.NexImmune, Inc.Avenue Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 0 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.08

Return on Equity

112.60%

Price to Book

-0.04

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

-28 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-70.0%

6 Months

-85.79%

1 Year

-99.39%

2 Years

-100.0%

3 Years

-99.78%

4 Years

-100.0%

5 Years

-100.0%

Windtree Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

7.23%

EBIT to Interest (avg)

-19.06

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

Tax Ratio

1.85%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.24%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-0.04

EV to EBIT

-0.79

EV to EBITDA

-0.81

EV to Capital Employed

12.90

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-1624.70%

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

Bullish

Bollinger Bands

Sideways

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Dow Theory

No Trend

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 2 Schemes (0.24%)

Foreign Institutions

Held by 3 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is -940.74% vs 38.64% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.40",
          "val2": "-4.60",
          "chgp": "26.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.10",
          "chgp": "200.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-27.70",
          "val2": "2.20",
          "chgp": "-1,359.09%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-28.10",
          "val2": "-2.70",
          "chgp": "-940.74%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 91.13% vs 48.21% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-24.90",
          "val2": "-17.50",
          "chgp": "-42.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.10",
          "chgp": "100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "23.80",
          "val2": "-3.10",
          "chgp": "867.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.80",
          "val2": "-20.30",
          "chgp": "91.13%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-3.40

-4.60

26.09%

Interest

0.30

0.10

200.00%

Exceptional Items

-27.70

2.20

-1,359.09%

Consolidate Net Profit

-28.10

-2.70

-940.74%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is -940.74% vs 38.64% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-24.90

-17.50

-42.29%

Interest

0.20

0.10

100.00%

Exceptional Items

23.80

-3.10

867.74%

Consolidate Net Profit

-1.80

-20.30

91.13%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 91.13% vs 48.21% in Dec 2023

All Annual Results

Company CV

About Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc.

Pharmaceuticals & Biotechnology

Windtree Therapeutics, Inc., formerly Discovery Laboratories, Inc., is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment. The Company's technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant, and drug delivery technologies being developed to enable non-invasive administration of aerosolized KL4 surfactant. The Company's core development program, AEROSURF (lucinactant for inhalation), is focused on improving the management of respiratory distress syndrome (RDS) in premature infants, a respiratory condition that can result in long-term respiratory problems, developmental delay and death.

Company Coordinates

Company Details

2600 Kelly Rd Ste 100 , WARRINGTON PA : 18976-3652

Tel: 1 215 4889300

http://www.windtreetx.com/

Registrar Details